Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

From Research to Practice: The Importance of Appropriate Outcome Selection, Measurement, and Reporting in Pediatric Mental Health Research.

Monga S, Offringa M, Butcher NJ, Szatmari P.

J Am Acad Child Adolesc Psychiatry. 2020 Apr;59(4):497-500. doi: 10.1016/j.jaac.2019.08.468.

PMID:
32220402
2.

Interaction of the brain-selective sulfotransferase SULT4A1 with other cytosolic sulfotransferases: effects on protein expression and function.

Idris M, Mitchell DJ, Gordon R, Sidharthan NP, Butcher NJ, Minchin RF.

Drug Metab Dispos. 2020 Mar 9. pii: dmd.119.089714. doi: 10.1124/dmd.119.089714. [Epub ahead of print]

3.

Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness.

Ching CRK, Gutman BA, Sun D, Villalon Reina J, Ragothaman A, Isaev D, Zavaliangos-Petropulu A, Lin A, Jonas RK, Kushan L, Pacheco-Hansen L, Vajdi A, Forsyth JK, Jalbrzikowski M, Bakker G, van Amelsvoort T, Antshel KM, Fremont W, Kates WR, Campbell LE, McCabe KL, Craig MC, Daly E, Gudbrandsen M, Murphy CM, Murphy DG, Murphy KC, Fiksinski A, Koops S, Vorstman J, Crowley TB, Emanuel BS, Gur RE, McDonald-McGinn DM, Roalf DR, Ruparel K, Schmitt JE, Zackai EH, Durdle CA, Goodrich-Hunsaker NJ, Simon TJ, Bassett AS, Butcher NJ, Chow EWC, Vila-Rodriguez F, Cunningham A, Doherty J, Linden DE, Moss H, Owen MJ, van den Bree M, Crossley NA, Repetto GM, Thompson PM, Bearden CE.

Am J Psychiatry. 2020 Feb 12:appiajp201919060583. doi: 10.1176/appi.ajp.2019.19060583. [Epub ahead of print]

PMID:
32046535
4.

Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion.

Cleynen I, Engchuan W, Hestand MS, Heung T, Holleman AM, Johnston HR, Monfeuga T, McDonald-McGinn DM, Gur RE, Morrow BE, Swillen A, Vorstman JAS, Bearden CE, Chow EWC, van den Bree M, Emanuel BS, Vermeesch JR, Warren ST, Owen MJ, Chopra P, Cutler DJ, Duncan R, Kotlar AV, Mulle JG, Voss AJ, Zwick ME, Diacou A, Golden A, Guo T, Lin JR, Wang T, Zhang Z, Zhao Y, Marshall C, Merico D, Jin A, Lilley B, Salmons HI, Tran O, Holmans P, Pardinas A, Walters JTR, Demaerel W, Boot E, Butcher NJ, Costain GA, Lowther C, Evers R, van Amelsvoort TAMJ, van Duin E, Vingerhoets C, Breckpot J, Devriendt K, Vergaelen E, Vogels A, Crowley TB, McGinn DE, Moss EM, Sharkus RJ, Unolt M, Zackai EH, Calkins ME, Gallagher RS, Gur RC, Tang SX, Fritsch R, Ornstein C, Repetto GM, Breetvelt E, Duijff SN, Fiksinski A, Moss H, Niarchou M, Murphy KC, Prasad SE, Daly EM, Gudbrandsen M, Murphy CM, Murphy DG, Buzzanca A, Fabio FD, Digilio MC, Pontillo M, Marino B, Vicari S, Coleman K, Cubells JF, Ousley OY, Carmel M, Gothelf D, Mekori-Domachevsky E, Michaelovsky E, Weinberger R, Weizman A, Kushan L, Jalbrzikowski M, Armando M, Eliez S, Sandini C, Schneider M, Béna FS, Antshel KM, Fremont W, Kates WR, Belzeaux R, Busa T, Philip N, Campbell LE, McCabe KL, Hooper SR, Schoch K, Shashi V, Simon TJ, Tassone F, Arango C, Fraguas D, García-Miñaúr S, Morey-Canyelles J, Rosell J, Suñer DH, Raventos-Simic J; International 22q11.2DS Brain and Behavior Consortium, Epstein MP, Williams NM, Bassett AS.

Mol Psychiatry. 2020 Feb 3. doi: 10.1038/s41380-020-0654-3. [Epub ahead of print]

PMID:
32015465
5.

Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review.

Pugliese M, Tingley K, Chow A, Pallone N, Smith M, Rahman A, Chakraborty P, Geraghty MT, Irwin J, Tessier L, Nicholls SG, Offringa M, Butcher NJ, Iverson R, Clifford TJ, Stockler S, Hutton B, Paik K, Tao J, Skidmore B, Coyle D, Duddy K, Dyack S, Greenberg CR, Ghai SJ, Karp N, Korngut L, Kronick J, MacKenzie A, MacKenzie J, Maranda B, Mitchell JJ, Potter M, Prasad C, Schulze A, Sparkes R, Taljaard M, Trakadis Y, Walia J, Potter BK; Canadian Inherited Metabolic Diseases Research Network.

Orphanet J Rare Dis. 2020 Jan 14;15(1):12. doi: 10.1186/s13023-019-1276-1. Review.

6.

Neurodevelopmental outcome descriptions in cohorts of extremely preterm children.

Ding S, Mew EJ, Chee-A-Tow A, Offringa M, Butcher NJ, Moore GP.

Arch Dis Child Fetal Neonatal Ed. 2020 Jan 13. pii: fetalneonatal-2019-318144. doi: 10.1136/archdischild-2019-318144. [Epub ahead of print]

PMID:
31932362
7.
8.

Training researchers in publication science: why, what, and how.

Butcher NJ, Tricco AC, Offringa M, Moher D, Galica J.

J Clin Epidemiol. 2020 Jan;117:165-167. doi: 10.1016/j.jclinepi.2019.08.007. Epub 2019 Aug 27. No abstract available.

PMID:
31465843
9.

Arylamine N-Acetyltransferase 1 Regulates Expression of Matrix Metalloproteinase 9 in Breast Cancer Cells: Role of Hypoxia-Inducible Factor 1-α.

Li P, Butcher NJ, Minchin RF.

Mol Pharmacol. 2019 Nov;96(5):573-579. doi: 10.1124/mol.119.117432. Epub 2019 Aug 23.

PMID:
31444237
10.

Neurobiological perspective of 22q11.2 deletion syndrome.

Zinkstok JR, Boot E, Bassett AS, Hiroi N, Butcher NJ, Vingerhoets C, Vorstman JAS, van Amelsvoort TAMJ.

Lancet Psychiatry. 2019 Nov;6(11):951-960. doi: 10.1016/S2215-0366(19)30076-8. Epub 2019 Aug 5. Review.

11.

Core outcome set for children with neurological impairment and tube feeding.

Joachim KC, Farid-Kapadia M, Butcher NJ, Chee-A-Tow A, Monsour A, Cohen E, Mahant S, Guttmann A, Offringa M; Complex Care COS Consensus Meeting Group.

Dev Med Child Neurol. 2020 Feb;62(2):201-206. doi: 10.1111/dmcn.14326. Epub 2019 Aug 1.

PMID:
31372989
12.

Counting What Counts: The Case for Harmonized Outcomes in Child and Youth Mental Health Research.

Szatmari P, Offringa M, Butcher NJ, Monga S.

J Am Acad Child Adolesc Psychiatry. 2019 Jul;58(7):656-658. doi: 10.1016/j.jaac.2019.02.016.

PMID:
31229181
13.

Establishing a core outcome set for treatment of uncomplicated appendicitis in children: study protocol for an international Delphi survey.

Knaapen M, Hall NJ, van der Lee JH, Butcher NJ, Offringa M, Van Heurn EWE, Bakx R, Gorter RR; Paediatric Appendicitis COS development group.

BMJ Open. 2019 May 22;9(5):e028861. doi: 10.1136/bmjopen-2018-028861.

14.

A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats.

Kaminskas LM, Williams CC, Leong NJ, Chan LJ, Butcher NJ, Feeney OM, Porter CJH, Tyssen D, Tachedjian G, Ascher DB.

Eur J Pharm Biopharm. 2019 Apr;137:218-226. doi: 10.1016/j.ejpb.2019.03.008. Epub 2019 Mar 6.

PMID:
30851352
15.

Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).

Butcher NJ, Monsour A, Mew EJ, Szatmari P, Pierro A, Kelly LE, Farid-Kapadia M, Chee-A-Tow A, Saeed L, Monga S, Ungar W, Terwee CB, Vohra S, Fergusson D, Askie LM, Williamson PR, Chan AW, Moher D, Offringa M.

Trials. 2019 Mar 6;20(1):161. doi: 10.1186/s13063-019-3248-0.

16.

Loss of human arylamine N-acetyltransferase I regulates mitochondrial function by inhibition of the pyruvate dehydrogenase complex.

Wang L, Minchin RF, Essebier PJ, Butcher NJ.

Int J Biochem Cell Biol. 2019 May;110:84-90. doi: 10.1016/j.biocel.2019.03.002. Epub 2019 Mar 2.

PMID:
30836144
17.

Guidance for reporting outcomes in clinical trials: scoping review protocol.

Butcher NJ, Mew EJ, Saeed L, Monsour A, Chee-A-Tow A, Chan AW, Moher D, Offringa M.

BMJ Open. 2019 Feb 19;9(2):e023001. doi: 10.1136/bmjopen-2018-023001.

18.

Outcomes reported in randomised clinical trials of major depressive disorder treatments in adolescents: a systematic scoping review protocol.

Monsour A, Mew EJ, Szatmari P, Patel S, Saeed L, Offringa M, Butcher NJ.

BMJ Open. 2019 Jan 15;9(1):e024191. doi: 10.1136/bmjopen-2018-024191. Review.

19.

The MBNL/CELF Splicing Factors Regulate Cytosolic Sulfotransferase 4A1 Protein Expression during Cell Differentiation.

Idris M, Butcher NJ, Minchin RF.

Drug Metab Dispos. 2019 Mar;47(3):314-319. doi: 10.1124/dmd.118.085290. Epub 2019 Jan 3.

PMID:
30606728
20.

Learning best-practices in journalology: course description and attendee insights into the inaugural EQUATOR Canada Publication School.

Galica J, Chee-A-Tow A, Gupta S, Jaiswal A, Monsour A, Tricco AC, Cobey KD, Butcher NJ.

BMC Proc. 2018 Aug 23;12(Suppl 10):18. doi: 10.1186/s12919-018-0155-4. eCollection 2018.

21.

Allosteric regulation of arylamine N-acetyltransferase 1 by adenosine triphosphate.

Minchin RF, Rosengren KJ, Burow R, Butcher NJ.

Biochem Pharmacol. 2018 Dec;158:153-160. doi: 10.1016/j.bcp.2018.10.013. Epub 2018 Oct 17.

PMID:
30342020
22.

Considerations for adaptive design in pediatric clinical trials: study protocol for a systematic review, mixed-methods study, and integrated knowledge translation plan.

Kelly LE, Dyson MP, Butcher NJ, Balshaw R, London AJ, Neilson CJ, Junker A, Mahmud SM, Driedger SM, Wang X.

Trials. 2018 Oct 19;19(1):572. doi: 10.1186/s13063-018-2934-7.

23.
24.

Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size.

Sun D, Ching CRK, Lin A, Forsyth JK, Kushan L, Vajdi A, Jalbrzikowski M, Hansen L, Villalon-Reina JE, Qu X, Jonas RK, van Amelsvoort T, Bakker G, Kates WR, Antshel KM, Fremont W, Campbell LE, McCabe KL, Daly E, Gudbrandsen M, Murphy CM, Murphy D, Craig M, Vorstman J, Fiksinski A, Koops S, Ruparel K, Roalf DR, Gur RE, Schmitt JE, Simon TJ, Goodrich-Hunsaker NJ, Durdle CA, Bassett AS, Chow EWC, Butcher NJ, Vila-Rodriguez F, Doherty J, Cunningham A, van den Bree MBM, Linden DEJ, Moss H, Owen MJ, Murphy KC, McDonald-McGinn DM, Emanuel B, van Erp TGM, Turner JA, Thompson PM, Bearden CE.

Mol Psychiatry. 2018 Jun 13. doi: 10.1038/s41380-018-0078-5. [Epub ahead of print]

25.

Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Butcher NJ, Boot E, Lang AE, Andrade D, Vorstman J, McDonald-McGinn D, Bassett AS.

Am J Med Genet A. 2018 Oct;176(10):2146-2159. doi: 10.1002/ajmg.a.38708. Epub 2018 May 19. Review.

26.

Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.

Boot E, Butcher NJ, Udow S, Marras C, Mok KY, Kaneko S, Barrett MJ, Prontera P, Berman BD, Masellis M, Dufournet B, Nguyen K, Charles P, Mutez E, Danaila T, Jacquette A, Colin O, Drapier S, Borg M, Fiksinski AM, Vergaelen E, Swillen A, Vogels A, Plate A, Perandones C, Gasser T, Clerinx K, Bourdain F, Mills K, Williams NM, Wood NW, Booij J, Lang AE, Bassett AS; International Research Group on 22q11.2DS-associated Parkinson's Disease.

Neurology. 2018 Jun 5;90(23):e2059-e2067. doi: 10.1212/WNL.0000000000005660. Epub 2018 May 11.

27.

Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Palmer LD, Butcher NJ, Boot E, Hodgkinson KA, Heung T, Chow EWC, Guna A, Crowley TB, Zackai E, McDonald-McGinn DM, Bassett AS.

Am J Med Genet A. 2018 Apr;176(4):936-944. doi: 10.1002/ajmg.a.38645.

28.

Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability.

Wang L, Minchin RF, Butcher NJ.

PLoS One. 2018 Mar 8;13(3):e0193560. doi: 10.1371/journal.pone.0193560. eCollection 2018.

29.

22q11.2 deletion syndrome lowers seizure threshold in adult patients without epilepsy.

Wither RG, Borlot F, MacDonald A, Butcher NJ, Chow EWC, Bassett AS, Andrade DM.

Epilepsia. 2017 Jun;58(6):1095-1101. doi: 10.1111/epi.13748. Epub 2017 Apr 27.

30.

Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease.

Butcher NJ, Merico D, Zarrei M, Ogura L, Marshall CR, Chow EWC, Lang AE, Scherer SW, Bassett AS.

PLoS One. 2017 Apr 21;12(4):e0173944. doi: 10.1371/journal.pone.0173944. eCollection 2017.

31.

Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease.

Butcher NJ, Horne MK, Mellick GD, Fowler CJ, Masters CL; AIBL research group, Minchin RF.

Pharmacogenomics J. 2018 Apr;18(2):209-214. doi: 10.1038/tpj.2017.4. Epub 2017 Apr 4.

PMID:
28374858
32.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.

Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, Repetto GM, Fritsch R, Chow EWC, Masellis M, Strafella AP, Lang AE, Bassett AS.

Brain. 2017 May 1;140(5):1371-1383. doi: 10.1093/brain/awx053.

PMID:
28369257
33.

Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway.

Witham KL, Minchin RF, Butcher NJ.

Biochem Pharmacol. 2017 Feb 1;125:93-100. doi: 10.1016/j.bcp.2016.11.015. Epub 2016 Nov 16.

PMID:
27865712
34.

Obesity in adults with 22q11.2 deletion syndrome.

Voll SL, Boot E, Butcher NJ, Cooper S, Heung T, Chow EW, Silversides CK, Bassett AS.

Genet Med. 2017 Feb;19(2):204-208. doi: 10.1038/gim.2016.98. Epub 2016 Aug 18.

35.

Drug delivery: Unravelling the stealth effect.

Butcher NJ, Mortimer GM, Minchin RF.

Nat Nanotechnol. 2016 Apr;11(4):310-1. doi: 10.1038/nnano.2016.6. Epub 2016 Feb 15. No abstract available.

PMID:
26878145
36.

Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome.

Merico D, Zarrei M, Costain G, Ogura L, Alipanahi B, Gazzellone MJ, Butcher NJ, Thiruvahindrapuram B, Nalpathamkalam T, Chow EW, Andrade DM, Frey BJ, Marshall CR, Scherer SW, Bassett AS.

G3 (Bethesda). 2015 Sep 16;5(11):2453-61. doi: 10.1534/g3.115.021345.

37.

Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms.

Guna A, Butcher NJ, Bassett AS.

J Neurodev Disord. 2015;7(1):18. doi: 10.1186/s11689-015-9113-x. Epub 2015 Jul 1.

38.

Pharmacological treatment of 22q11.2 deletion syndrome-related psychoses.

Boot E, Butcher NJ, Vorstman JA, van Amelsvoort TA, Fung WL, Bassett AS.

Pharmacopsychiatry. 2015 Sep;48(6):219-20. doi: 10.1055/s-0035-1554645. Epub 2015 Jun 19.

PMID:
26091278
39.

Fetal growth and gestational factors as predictors of schizophrenia in 22q11.2 deletion syndrome.

Van L, Butcher NJ, Costain G, Ogura L, Chow EW, Bassett AS.

Genet Med. 2016 Apr;18(4):350-5. doi: 10.1038/gim.2015.84. Epub 2015 Jun 18.

PMID:
26087175
40.

Response to clozapine in a clinically identifiable subtype of schizophrenia.

Butcher NJ, Fung WL, Fitzpatrick L, Guna A, Andrade DM, Lang AE, Chow EW, Bassett AS.

Br J Psychiatry. 2015 Jun;206(6):484-91. doi: 10.1192/bjp.bp.114.151837. Epub 2015 Mar 5.

41.

Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.

Vorstman JA, Breetvelt EJ, Duijff SN, Eliez S, Schneider M, Jalbrzikowski M, Armando M, Vicari S, Shashi V, Hooper SR, Chow EW, Fung WL, Butcher NJ, Young DA, McDonald-McGinn DM, Vogels A, van Amelsvoort T, Gothelf D, Weinberger R, Weizman A, Klaassen PW, Koops S, Kates WR, Antshel KM, Simon TJ, Ousley OY, Swillen A, Gur RE, Bearden CE, Kahn RS, Bassett AS; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

JAMA Psychiatry. 2015 Apr;72(4):377-85. doi: 10.1001/jamapsychiatry.2014.2671.

42.

Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.

Boot E, Butcher NJ, van Amelsvoort TA, Lang AE, Marras C, Pondal M, Andrade DM, Fung WL, Bassett AS.

Am J Med Genet A. 2015 Mar;167A(3):639-45. doi: 10.1002/ajmg.a.36928. Epub 2015 Feb 13.

43.

The role of lysine(100) in the binding of acetylcoenzyme A to human arylamine N-acetyltransferase 1: implications for other acetyltransferases.

Minchin RF, Butcher NJ.

Biochem Pharmacol. 2015 Apr 1;94(3):195-202. doi: 10.1016/j.bcp.2015.01.015. Epub 2015 Feb 4.

PMID:
25660616
44.

Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.

Tiang JM, Butcher NJ, Minchin RF.

Cancer Med. 2015 Apr;4(4):565-74. doi: 10.1002/cam4.415. Epub 2015 Jan 28.

45.

Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, Chung B, Cytrynbaum C, Faghfoury H, Fishman L, García-Miñaúr S, George S, Lang AE, Repetto G, Shugar A, Silversides C, Swillen A, van Amelsvoort T, McDonald-McGinn DM, Bassett AS.

Genet Med. 2015 Aug;17(8):599-609. doi: 10.1038/gim.2014.175. Epub 2015 Jan 8. Review.

46.

MicroRNA Dysregulation, Gene Networks, and Risk for Schizophrenia in 22q11.2 Deletion Syndrome.

Merico D, Costain G, Butcher NJ, Warnica W, Ogura L, Alfred SE, Brzustowicz LM, Bassett AS.

Front Neurol. 2014 Nov 21;5:238. doi: 10.3389/fneur.2014.00238. eCollection 2014.

47.

Expression of the orphan cytosolic sulfotransferase SULT4A1 and its major splice variant in human tissues and cells: dimerization, degradation and polyubiquitination.

Sidharthan NP, Butcher NJ, Mitchell DJ, Minchin RF.

PLoS One. 2014 Jul 2;9(7):e101520. doi: 10.1371/journal.pone.0101520. eCollection 2014.

48.

Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials.

Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ, Minchin RF.

ACS Nano. 2014 Apr 22;8(4):3357-66. doi: 10.1021/nn405830g. Epub 2014 Mar 27.

PMID:
24617595
49.

Interaction of human arylamine N-acetyltransferase 1 with different nanomaterials.

Deng ZJ, Butcher NJ, Mortimer GM, Jia Z, Monteiro MJ, Martin DJ, Minchin RF.

Drug Metab Dispos. 2014 Mar;42(3):377-83. doi: 10.1124/dmd.113.055988. Epub 2013 Dec 17.

PMID:
24346836
50.

5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion.

Witham KL, Butcher NJ, Sugamori KS, Brenneman D, Grant DM, Minchin RF.

PLoS One. 2013 Oct 25;8(10):e77923. doi: 10.1371/journal.pone.0077923. eCollection 2013.

Supplemental Content

Loading ...
Support Center